Osimertinib regressed an EGFR-mutant lung-adenocarcinoma bone-metastasis mouse model and increased long-term survival

Area of Science:

• Oncology
• Pharmacology
• Orthopedics

Background:

• Bone metastasis is common in non-small cell lung cancer (NSCLC).
• Osimertinib and bevacizumab (BV) efficacy in NSCLC bone metastasis remains understudied.
• Targeting bone metastasis is crucial for improving NSCLC patient outcomes.

Purpose of the Study:

• To investigate the efficacy of osimertinib, with and without bevacizumab, in treating non-small cell lung cancer bone metastasis.
• To evaluate the impact of these treatments on tumor regression, survival, and bone remodeling in a preclinical model.

Main Methods:

• A preclinical mouse model of NSCLC bone metastasis was established using H1975-RFP cells injected into the tibia.
• Mice were randomized into four groups: Control, bevacizumab alone, osimertinib alone, and combination therapy.
• Tumor growth and bone remodeling were monitored using non-invasive fluorescence imaging.

Main Results:

• Osimertinib, both as a single agent and in combination with bevacizumab, demonstrated significant tumor regression.
• Treatment with osimertinib (with or without bevacizumab) led to increased survival rates in the mouse models.
• Evidence of bone remodeling was observed in the treated groups, indicating a positive effect on bone structure.

Conclusions:

• Osimertinib shows promise as a therapeutic option for non-small cell lung cancer patients with bone metastasis.
• Combination therapy with bevacizumab may enhance the efficacy of osimertinib in this setting.
• Further clinical investigation is warranted to confirm these findings in NSCLC patients.